Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3460 Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Introduction: Clinical trial data show prolonged progression-free survival (PFS) with LAN in metastatic enteropancreatic NET; real-world data may demonstrate effectiveness in routine care.

Conference:

Presenting Author: Alonso T

Authors: Alonso-Gordoa T, Capdevila J, González E, Teulé A, Anido U,

Keywords: net, pancreas, lanreotide, clinical practice,

#1356 Safety and Compliance of Capecitabine and Temozolomide in Patients with Advanced Neuroendocrine Tumours

Introduction: Capecitabine-temozolomide (CAPTEM) is a treatment option in patients (pts) with neuroendocrine tumours. Although efficacy data has been reported, no detailed safety information exists.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Papaxoinis G

Authors: Papaxoinis G, McCallum L, Nasralla M, Hubner R, McNamara M,

Keywords: capecitabine, temozolomide, NET,

#1354 Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome

Introduction: Telotristat etiprate (TE) reduces serotonin production. In TELESTAR, a phase 3 study in patients (pts) with carcinoid syndrome (CS) on somatostatin analogues with ≥4 bowel movements (BM) per day, TE significantly reduced BM frequency (freq). Overall (n=135), durable response (DR, ≥30% reduction in BMs/day for ≥50% of the study period) was observed in 44% (250 mg tid) and 42% (500 mg tid), vs 20% on placebo (PBO); p≤0.02 for each TE vs. PBO. A subset with similar demographics to the overall trial was interviewed.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Pavel M, Hörsch D, Anthony L, Ervin C, Kulke M,

Keywords: serotonin, bowel movement, durable response, treatment satisfaction,

#1178 Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study

Introduction: CS associated with NETs can have a negative impact on patients’ QoL.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Ruszniewski P, Caplin M, Valle J, Lombard-Bohas C, Poston G,

Keywords: quality of life,